Prime Medicine PRME 深 沪
等待开盘 11-05 09:30:00 美东时间
4.97
+0.420
+9.23%
华盛通- 最 高5.12
- 今 开4.75
- 成交量 439.73万股
- 最 低 4.5899
- 昨 收 4.55
- 总市值 9.01亿
- 52周最高 5.9099
- 市盈率 静 --
- 换手率 2.42%
- 52周最低 2.67
- 委 比 33.33%
- 总股本 1.81亿
- 历史最高 21.73
- 量 比 0.54
- 振 幅 11.65%
- 历史最低 1.11
- 每 手 1
- 风险率 0.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AI制药的新故事：前高盛分析师撑起一人药企，Anthropic出手收购
财联社10月28日讯（编辑 史正丞）正冲刺万亿美元级IPO估值的大模型巨头Anthropic，收购了一家只有一名全职员工的药企。 当地时间10月27日，Ant...
10-28 16:09
Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones index surging over 250 points on Tuesday. Shares of Apogee Enterprises Inc (NASDAQ:APOG) rose sharply after the company announced better-than-expected second-quarter financial results and raised its FY27 guidance above estimates. Apogee Enterprises reporte...
10-06 21:59
Costco Wholesale, Scholastic and 3 Stocks to Watch Heading Into Friday
With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Tamboran Resources Corp. (NYSE:TBN) to post a quarterly loss of 30 cents per share on revenue of $3.82 million before the opening bell, according t...
09-25 15:24
FDA Clears Prime Medicine’s IND Application For PM647, Investigational In Vivo Prime Editor For Alpha-1 Antitrypsin Deficiency
FDA Clears Prime Medicine’s IND Application For PM647, Investigational In Vivo Prime Editor For Alpha-1 Antitrypsin Deficiency
09-25 04:02
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
Prime Medicine's PM647, an in vivo Prime Editor for Alpha-1 Antitrypsin Deficiency (AATD), has received FDA IND clearance, allowing clinical studies to begin in the U.S. PM647 aims to correct the E342K (Pi*Z) mutation in the SERPINA1 gene, addressing both lung and liver manifestations of AATD. The Phase 1/2 trial will evaluate safety, tolerability, and efficacy in adults with AATD, initially targeting lung-only manifestations before expanding to ...
09-24 20:01
Anthropic IPO前亮科研牌：Claude“自主发现”类CRISPR系统，基因编辑板块遭遇“AI替代焦虑”
周三，美股基因编辑公司股价走低。此前，Anthropic宣布，其AI模型Claude“自主发现”了一种类似于基因编辑工具CRISPR的新型酶系统。 个股方面，...
09-24 07:21
Gene editing stocks fall after Anthropic’s CRISPR-like discovery
Gene editing companies traded lower on Wednesday after Anthropic (ANTHRO) said that its AI model Claude has “autonomously discovered” a new enzyme system similar to the gene-editing tool CRISPR. Notab...
09-24 02:33
Prime Medicine to Participate in Upcoming Investor Conferences
Prime Medicine, Inc. announced that its management will participate in three upcoming conferences: the Wells Fargo Healthcare Conference in Boston on September 10, the H.C. Wainwright Global Investment Conference in New York on September 15, and the Morgan Stanley Global Healthcare Conference in New York on September 16. Live audio webcasts of the fireside chats will be available on the company’s website, with replays accessible for 90 days. Prim...
09-03 12:00
Moderna(MRNA.US)mRNA癌症疫苗重大突破引爆市场情绪！生物科技板块估值重估可能才刚开始
生物科技行业在很大程度上受到临床事件的驱动——一项三期临床试验的成功或失败，不仅可以推动直接参与其中的公司股价大幅波动，也可能影响它们所代表的整个治疗技术类别...
08-25 11:45
